Loading viewer...
investor_presentation
Format: PDF investor_presentation
39thAnnual J.P . Morgan Healthcare Conference Howard Robin President & CEO January 11, 2021
J.P . Morgan Healthcare Conference
January 11, 20212This presentation includes forward -looking statements regarding Nektar’s proprietary drug
candidates, the timing of the start of and plans for ongoing or planned clinical trials with
partners, the therapeutic potential of our drug candidates, the timing and outcome of regulatory
decisions, and future availability of clinical trial data. Actual results could differ materially, and
these statements are subject to important risks detailed in Nektar's filings with the SEC including
the Form 10 -Q filed on November 6, 2020. Nektar undertakes no obligation to update forward-
looking statements as a result of new information or otherwise.Nektar is Developing Innovative Medicines for Patients with Cancer
and Autoimmune Diseases
NKTR -358Systemic Lupus Erythematosus LY3471851 / NKTR -358
Ulcerative Colitis LY3471851 / NKTR -358
Psoriasis LY3471851 / NKTR -358
Atopic Dermatitis LY3471851 / NKTR -358
BEMPEG COVID -19 BEMPEG
NKTR -255 Virology NKTR -255Bempegaldesleukin
(NKTR -214)Metastatic Melanoma BEMPEG + OPDIVO® vs. OPDIVO®
Renal Cell Carcinoma BEMPEG + OPDIVO® vs. TKI
Muscle -invasive Bladder Cancer BEMPEG + OPDIVO® vs. OPDIVO®
Adjuvant Melanoma BEMPEG + OPDIVO® vs. OPDIVO®
Bladder Cancer BEMPEG + OPDIVO®
Renal Cell Carcinoma BEMPEG + OPDIVO® + TKI
1L NSCLC BEMPEG + KEYTRUDA®
Head & Neck SCC BEMPEG + VB10.NEO
NKTR -262 Multiple Solid Tumors NKTR -262 + BEMPEG
NKTR -255R/R NHL or Multiple Myeloma NKTR -255 + RITUXAN®or DARZALEX FASPRO®
Head & Neck and Colorectal NKTR -255 + ERBITUX®
Program Indication Study Preclinical Phase 1 Phase 2 Phase 3
Registrational Study
Registrational Study
Registrational Study
Preview truncated — download the full document for the complete content.
conference
28 Pages
investor_presentation
16 Pages
Verizon Communications Inc.
investor_presentation
ConnectOne Bancorp
investor_presentation
Boral Limited